Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Endocrinology (1986) 119:146775
Years of research on the safety and effectiveness of the drugs is required
This GLP-1 (also written as GLP-one or GLP 1) companion supplement addresses the specific nutritional gaps created by GLP-1 receptor agonist medications (such as Ozempic, Wegovy, Mounjaro, and Zepbound). GLP-1 medications work partly by suppressing appetite and slowing gastric emptying. That's the mechanism behind the weight loss. But less food in means fewer vitamins and minerals in and the research now shows this isn't a theoretical concern. Butsch et al. (2025), the largest of the six studies in the Urbina review, tracked 461,382 GLP-1 users and found 22.4% had a new nutritional deficiency diagnosis within 12 months. Vitamin D was most common (13.6%), followed by nutritional anemia (4%), iron deficiency (3.2%), and B vitamin deficiency (2.6%). In a smaller dietary study (Johnson et al. 2025, Frontiers in Nutrition), 64% of GLP-1 users didn't meet iron intake recommendations, and 72% fell short on calcium.* This GLP-1 supplement covers the five most at-risk nutrients with bioavailable forms: methylcobalamin B12, chelated iron, chelated zinc, 5-MTHF folate, and vitamin D3
For longer-term semaglutide storage considerations , the 28-day post-reconstitution rule is non-negotiable
